IBJNews

Endocyte's $86M IPO plan a boon for Indiana, investors

Back to TopCommentsE-mailPrintBookmark and Share
Greg Andrews

Endocyte Inc. has zero sales and a work force of just 54. But the fledgling life sciences firm may end up as one of Indiana’s most powerful economic engines of the 21st century.

Or at least that’s what many of the leaders of Indiana’s life sciences and entrepreneurial communities have been hoping for years. And now that the cancer-fighting West Lafayette firm has filed for an $86 million initial public offering, that reality seems tantalizingly close.

A successful IPO would be huge on many levels.

For the state of Indiana, it would help validate key parts of its economic-development strategy. From 2001 through 2004, the company received a total of $4 million in grants from the state’s 21st Century Research and Technology Fund—money that helped sustain it at a crucial time and drew in tens of millions of dollars more in venture capital.

Endocyte also demonstrates the potential payoff from the state’s push to transfer promising new technologies from academic laboratories to startup companies. Philip Low, a Purdue University chemistry professor who serves as Endocyte’s chief science officer, led the research team that developed the company’s treatment—an approach that delivers high doses of cancer drugs to diseased cells while leaving healthy cells untouched.

Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital, Clarian Health Ventures and the Indiana Future Fund.

The life sciences initiative BioCrossroads launched the Future Fund in 2003, raising $73 million from the Public Employees’ Retirement Fund, Ball State University, OneAmerica, WellPoint Inc. and others. The money then flowed to six venture capital firms, including San Francisco-based Burrill & Co., which became one of Endocyte’s biggest investors.

An even larger investor is the pension fund of the Indianapolis-based Christian Church (Disciples of Christ). Endocyte’s IPO filing, submitted to the Securities and Exchange Commission Aug. 17, said the fund invested more than $10.3 million and holds a 15-percent stake. Pension fund President James Hamlett declined to comment, citing regulatory restrictions while an IPO is pending.

P. Ron Ellis, Endocyte’s CEO, also declined to comment, citing the same restrictions.

The company’s 150-page IPO filing, however, tells an intriguing story—one of a company that slugged through years of research in its quest to bring a ground-breaking treatment to market. The company operates out of 14,000 square feet at Purdue University Research Park as well as a 4,000-square-foot corporate office in Indianapolis.

Here’s how Endocyte’s technology works: The cancer-fighting drug is linked to a substance that targets receptors that are overexpressed in diseased cells relative to healthy cells. Endocyte uses companion imaging technology to identify patients who have the overexpressed receptors and thus are more likely to benefit from treatment.

It’s a powerful combination. “This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone,” Endocyte says in its filing.

Endocyte now is on the cusp of commercialization. In early 2011, it expects to begin enrollment in a phase-three trial for an extremely difficult-to-treat form of ovarian cancer. Women receiving the treatment in a phase 2 trial saw a 105-percent improvement in progression-free survival compared with women receiving the standard therapy.

The company also is working on other treatments, including one for non-small-cell lung cancer that has completed a phase two trial.

For now, however, Endocyte is piling up massive losses, burning through the more than $90 million in private investment it’s raised since forming in 1995. Over just the past three years, losses have totaled $49 million. And there’s no guarantee of ultimate success, said David Menlow, president of IPOfinancial.com in Millburn, N.J.

He said life sciences firms often go public before their products have won U.S. Food and Drug Administration approval. Some ultimately succeed spectacularly, he said, while others flame out. Some investors stay on the sidelines “because they don’t feel like buying lottery tickets,” he said.

Yet economic development leaders are focusing on the upside—and what Endocyte’s long-term success would mean for efforts to cast Indiana as a hotbed for life sciences entrepreneurism.

“For us, as this moves ahead, it is proof of concept that Indiana companies can go the distance,” said David Johnson, CEO of BioCrossroads.

And—oh, yeah—there’s the potential benefit to humanity, too.

“The product itself has the promise of saving tens of thousands if not millions of lives in this country and around the world,” said Mitch Roob, Indiana’s secretary of commerce.•

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Of what value is selling alcoholic beverages to State Fair patrons when there are many families with children attending. Is this the message we want to give children attending and participating in the Fair, another venue with alooholic consumption onsite. Is this to promote beer and wine production in the state which are great for the breweries and wineries, but where does this end up 10-15 years from now, lots more drinkers for the alcoholic contents. If these drinks are so important, why not remove the alcohol content and the flavor and drink itself similar to soft drinks would be the novelty, not the alcoholic content and its affects on the drinker. There is no social or material benefit from drinking alcoholic beverages, mostly people want to get slightly or highly drunk.

  2. I did;nt know anyone in Indiana could count- WHY did they NOT SAY just HOW this would be enforced? Because it WON;T! NOW- with that said- BIG BROTHER is ALIVE in this Article-why take any comment if it won't appease YOU PEOPLE- that's NOT American- with EVERYTHING you indicated is NOT said-I can see WHY it say's o Comments- YOU are COMMIES- BIG BROTHER and most likely- voted for Obama!

  3. In Europe there are schools for hairdressing but you don't get a license afterwards but you are required to assist in turkey and Italy its 7 years in japan it's 10 years England 2 so these people who assist know how to do hair their not just anybody and if your an owner and you hire someone with no experience then ur an idiot I've known stylist from different countries with no license but they are professional clean and safe they have no license but they have experience a license doesn't mean anything look at all the bad hairdressers in the world that have fried peoples hair okay but they have a license doesn't make them a professional at their job I think they should get rid of it because stateboard robs stylist and owners and they fine you for the dumbest f***ing things oh ur license isn't displayed 100$ oh ur wearing open toe shoes fine, oh there's ONE HAIR IN UR BRUSH that's a fine it's like really? So I think they need to go or ease up on their regulations because their too strict

  4. Exciting times in Carmel.

  5. Twenty years ago when we moved to Indy I was a stay at home mom and knew not very many people.WIBC was my family and friends for the most part. It was informative, civil, and humerous with Dave the KING. Terri, Jeff, Stever, Big Joe, Matt, Pat and Crumie. I loved them all, and they seemed to love each other. I didn't mind Greg Garrison, but I was not a Rush fan. NOW I can't stand Chicks and all their giggly opinions. Tony Katz is to abrasive that early in the morning(or really any time). I will tune in on Saturday morning for the usual fun and priceless information from Pat and Crumie, mornings it will be 90.1

ADVERTISEMENT